We are live on !
Find out more
Profund Advisors Portfolio holdings
AUM
$3.48B
Turnover
14.37%
1-Year Est. Return
66.96%
ProFund Advisors manages the ProFunds mutual funds, which include index funds across sectors, bonds, currencies and crypto, as well as leveraged and inverse funds. The ProFunds brand dates from 1997, and its affiliate ProShares began offering leveraged and inverse ETFs in 2006. The Bitcoin ProFund tracks bitcoin futures rather than holding bitcoin itself.
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+66.96%
3 Year Est. Return
+258.11%
5 Year Est. Return
+342.15%
10 Year Est. Return
+1,333.1%
AUM
$3.48B
AUM Growth
-$153M
(-4.2%)
Cap. Flow
-$155M
Cap. Flow % of AUM
Cap. Flow %
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
41.36%
Holding
1,225
New
50
Increased
319
Reduced
729
Closed
126
Avg Time Held
6.2
years
Top 10 Avg Time Held
4.5
years
Top 20 Avg Time Held
5.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$37.8M |
| 2 |
Alumis Inc
ALMS
|
+$2.98M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$1.65M |
| 4 |
Reddit
RDDT
|
+$1.57M |
| 5 |
Septerna Inc
SEPN
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$46.8M |
| 2 |
Broadcom
AVGO
|
+$15.2M |
| 3 |
Micron Technology
MU
|
+$13.3M |
| 4 |
Apple
AAPL
|
+$12.8M |
| 5 |
Advanced Micro Devices
AMD
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.2% |
| 2 | Healthcare | 10.88% |
| 3 | Communication Services | 8.15% |
| 4 | Consumer Discretionary | 7.38% |
| 5 | Industrials | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
Vaxcyte
PCVX
$10B
| $1.81M | 0.05% |
31,750
-527
| -2% | -$30.7K |
2023 Q1
14 quarters
|
|
227
Jazz Pharmaceuticals
JAZZ
$15.5B
| $1.8M | 0.05% |
7,783
+5,256
| +208% | +$1.3M |
2013 Q3
52 quarters
|
|
228
ServiceNow
NOW
$106B
| $1.8M | 0.05% |
13,398
-1,470
| -10% | -$181K |
2017 Q1
38 quarters
|
|
229
Carvana
CVNA
$79.8B
| $1.79M | 0.05% |
28,558
-1,854
| -6% | -$127K |
2023 Q3
12 quarters
|
|
230
Supernus, Inc. Common Stock
SUPN
$6.17B
| $1.78M | 0.05% |
49,650
+36,188
| +269% | +$1.37M |
2025 Q4
3 quarters
|
|
231
Zoetis
ZTS
$34.1B
| $1.78M | 0.05% |
25,433
+17,649
| +227% | +$1.32M |
2013 Q2
53 quarters
|
|
232
Corcept Therapeutics
CORT
$7.88B
| $1.77M | 0.05% |
15,351
+8,700
| +131% | +$936K |
2026 Q1
2 quarters
|
|
233
Rhythm Pharmaceuticals
RYTM
$7.97B
| $1.76M | 0.05% |
18,488
+1,683
| +10% | +$180K |
2023 Q1
14 quarters
|
|
234
Veracyte
VCYT
$1.96B
| $1.74M | 0.05% |
37,882
+13,188
| +53% | +$636K |
2023 Q1
14 quarters
|
|
235
Ionis Pharmaceuticals
IONS
$4.84B
| $1.73M | 0.05% |
38,639
+20,318
| +111% | +$1.15M |
2013 Q2
53 quarters
|
|
236
Elanco Animal Health
ELAN
$13.4B
| $1.7M | 0.05% |
76,116
+53,697
| +240% | +$1.3M |
2019 Q1
30 quarters
|
|
237
CG Oncology
CGON
$6.65B
| $1.7M | 0.05% |
24,035
-1,937
| -7% | -$142K |
2024 Q2
9 quarters
|
|
238
ImmunityBio
IBRX
$6.4B
| $1.69M | 0.05% |
179,021
+2,518
| +1% | +$20.1K |
2023 Q4
11 quarters
|
|
239
eBay
EBAY
$53.1B
| $1.69M | 0.05% |
15,905
-3,012
| -16% | -$328K |
2013 Q2
53 quarters
|
|
|
240
DELISTED
Supernus Pharmaceuticals
SUPN
| $1.68M | 0.05% |
39,129
+30,456
| +351% | +$1.39M |
2023 Q1
14 quarters
|
|
241
Okta
OKTA
$32B
| $1.68M | 0.05% |
8,038
-706
| -8% | -$112K |
2018 Q1
34 quarters
|
|
242
Occidental Petroleum
OXY
$58.7B
| $1.68M | 0.05% |
30,279
-8,084
| -21% | -$462K |
2013 Q2
53 quarters
|
|
243
Perrigo
PRGO
$2.25B
| $1.67M | 0.05% |
113,418
+84,207
| +288% | +$1.06M |
2013 Q2
53 quarters
|
|
244
ANI Pharmaceuticals
ANIP
$1.62B
| $1.65M | 0.05% |
22,656
+18,489
| +444% | +$1.42M |
2024 Q2
9 quarters
|
|
245
Viking Therapeutics
VKTX
$3.73B
| $1.64M | 0.05% |
50,459
+2,052
| +4% | +$71.1K |
2023 Q1
14 quarters
|
|
246
Definium Therapeutics
DFTX
$4.39B
| $1.63M | 0.05% |
42,885
+29,314
| +216% | +$1.24M |
2024 Q2
9 quarters
|
|
247
Organon & Co
OGN
$3.65B
| $1.63M | 0.05% |
119,069
+93,228
| +361% | +$1.27M |
2021 Q2
21 quarters
|
|
248
Mirum Pharmaceuticals
MIRM
$6.14B
| $1.62M | 0.05% |
18,939
+3,676
| +24% | +$384K |
2023 Q1
14 quarters
|
|
249
Credo Technology Group
CRDO
$24.7B
| $1.62M | 0.05% |
8,306
-681
| -8% | -$147K |
2025 Q2
5 quarters
|
|
250
Entegris
ENTG
$22.5B
| $1.62M | 0.05% |
10,500
-1,034
| -9% | -$146K |
2017 Q3
36 quarters
|
|
Similar funds
TC
SHIM
Profund Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Profund Advisors held 1,225 positions worth $3.48B, down 4.2% from $3.64B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Profund Advisors withdrew a net $155M in Q3 2026, closing 126 positions and reducing 729 holdings. Its most notable exit was Electronic Arts, an estimated $5.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 54% of assets, down from 56% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Profund Advisors opened a new position in SpaceX worth $41.3M.
- Profund Advisors's largest Q3 2026 buy was SpaceX: 273,453 shares worth $41.3M.
- Profund Advisors added most to Alumis Inc in Q3 2026, an estimated $2.98M increase.
- Profund Advisors's biggest Q3 2026 reduction was NVIDIA, cutting an estimated $46.8M.
- Profund Advisors fully exited Electronic Arts in Q3 2026, selling an estimated $5.2M.
- Profund Advisors's ten largest holdings make up 41% of its $3.48B portfolio in Q3 2026.
- Profund Advisors opened 50 new positions and closed 126 in Q3 2026.
- Profund Advisors's portfolio value fell 4.2% quarter-over-quarter to $3.48B.
Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.